Trial Profile
Phase I Dose Escalation of Pazopanib Plus TH302 in Advanced Solid Tumors Followed by an Expanded Cohort in Pancreatic Neuroendocrine Tumors.
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 20 Aug 2023
Price :
$35
*
At a glance
- Drugs Evofosfamide (Primary) ; Pazopanib (Primary)
- Indications Neuroendocrine tumours; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- 01 Sep 2011 New trial record